Interesting talks from @GeorgeTsokos. Response to Ustekinumab in #lupus trial was associated with reduction in IFN-gamma (IFN-II) but not IL17 (A & F), 22 or IFN-I signature (IFN-alpha) #EULAR2019 https://t.co/xZP4qjSUnH